InMed Pharmaceuticals Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Expert in Cannabinoid Research – Form 8-K

InMed expands its patent portfolio with new cannabinoid analogues and

Advanced collaboration agreement with a leading expert in cannabinoid research

Expands library of proprietary cannabinoid analogs for pharmaceutical R&D

Research collaboration initiated to screen analogues for therapeutic purposes

Vancouver, BC and South San Francisco, CA – April 28, 2022 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and marketing of rare cannabinoids, is pleased to announce the publication of a patent application in North America for several cannabinoid analogues. This patent application contains general claims concerning their molecular structure, their uses and their methods of manufacture.

Titled “Cannabinoid Analogs and Methods for their Preparation,” the patent application describes several new chemical compounds related to cannabinoids that have not been previously described. If granted, the broad patent application allows for the creation of multiple variants of new cannabinoid compounds, yielding a robust library of New Proprietary Chemical Entities (“NCEs”).

Scientists at BayMedica, LLC, a subsidiary of InMed in the United States, designed and produced these cannabinoid analogs. These NCEs are expected to offer similar or enhanced therapeutic effects compared to their parent (natural) cannabinoid with modifications that could make them prime candidates for treating specific diseases.

Eric Hsu, SVP, Preclinical Research and Development for InMed commented; “We believe that rare cannabinoids have enormous therapeutic potential that can address a number of unmet medical needs. This patent covers the selective modification of natural cannabinoids to target specific properties for pharmaceutical development. Such patent protection is an important element to ensure long-term commercialization. exclusivity as we continue to invest in R&D.”

InMed has initiated a research collaboration with the Department of Applied Biotechnological and Clinical Sciences of the University of L’Aquila (Italy) in the laboratory of Dr. Mauro Maccarrone, international expert in cannabinoid research and founding member of the European Alliance cannabinoid research. He is also the 2007 recipient of the prestigious Ester Fride Award for Basic Research from the International Association for Cannabinoid Medicines and the 2016 recipient of the prestigious Mechoulam Award from the International Cannabinoid Research Society. Dr. Maccarrone’s lab will examine the company’s new cannabinoid analogs to investigate pharmacological properties and potential therapeutic uses.

Build a strong NCE patent library

The patent application covers technology that enables the creation of libraries of RCEs that can be compared to other drugs to select candidates for advancement. Cannabinoid analogs were made in a biosynthetic process using yeast S.cerevisiae, which is commonly used to produce therapeutic biologics and vaccines.

The filing of this patent application in a number of global jurisdictions further underscores the Company’s commitment to developing NCEs and enhancing rare cannabinoid R&D opportunities.

Why look for cannabinoid analogues?

Unlike natural cannabinoids isolated from the plant which are not patentable, these cannabinoid analogs are patentable. Benefits may include:

Target certain physiological outcomes in specific diseases;

Improve the safety profile of natural cannabinoids;

Improve the ability to integrate with specific delivery technologies; and

Protect long-term research investments and business opportunities.

Learn more about InMed’s cannabinoid analogues:

New Patentable Cannabinoid Analogs | InMed Pharmaceuticals

Learn more about InMed’s cannabinoids in development: https://www.inmedpharma.com/pharmaceutical/cannabinoids-in-development/

About InMed: InMed Pharmaceuticals is a world leader in the research, development, manufacturing and marketing of rare cannabinoids. Together with its subsidiary BayMedica, LLC, the company has unparalleled cannabinoid manufacturing capabilities to serve an array of consumer markets, including pharmaceuticals, health and wellness. InMed is also a clinical-stage company developing a pipeline of rare therapeutic cannabinoids and dedicated to providing new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com and www.baymedica.com.

Investor contacts:

Colin Clancy

Senior Director, Investor Relations

Such. : +1.604.416.0999

Email: cclancy@inmedpharma.com

Caution Regarding Forward-Looking Information:

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information contained in this press release includes statements about: expanding the patent portfolio with new cannabinoid analogs; advancing the collaboration agreement with a leading expert in cannabinoid research; screening of analogues for therapeutic purposes; publication of a patent application in North America for several cannabinoid analogues; the patent has general claims to molecular structure, uses and methods of manufacture; NCEs are expected to offer similar or enhanced therapeutic effects over their parent (natural) cannabinoid with modifications that may make them prime candidates for treating specific diseases; cannabinoids have enormous therapeutic potential that can address a number of unmet medical needs; patent application covering a technology allowing the creation of NCE libraries that can be compared to other drugs in order to select candidates for advancement; screen the Company’s novel cannabinoid analogs to study pharmacological properties and potential therapeutic uses; the benefits of analogs which may include targeting certain physiological outcomes in specific diseases, improving the safety profile of natural cannabinoids; improve the ability to integrate with specific delivery technologies; protect long-term research investments and business opportunities; to be a world leader in the research, development, manufacturing and development of rare cannabinoids; and offer new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs.

With respect to the forward-looking information contained in this press release, InMed has made numerous assumptions. Although InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

In addition, there are known and unknown risk factors that could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in the present. A full discussion of the risks and uncertainties facing InMed’s stand-alone businesses is disclosed in InMed’s Annual Report on Form 10-K and in other filings with the Security and Exchange Commission at www.sec. gov.

All forward-looking information contained herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update such forward-looking information or to publicly announce the outcome of any revision of any of the forward-looking information. forward-looking statements contained herein. to reflect future results, events or developments, except as required by law.

Comments are closed.